Advertisement

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement

Jul

15

Today In Oncology

Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors

American Cancer Society Reports Latest Global Cancer Statistics

Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors

Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy

Advertisement

© 2026 HSP News Service, L.L.C.